Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Connecting terms with OR broadens your search to give more results …more on search operators – . EDGAR Online -K Glimpse (USA) – -K SEPRACOR INC /DE/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. ——————————————————————————– FORM -K CURRENT REPORT Pursuant to Section or (d) of the Securities Exchange Act of Date of Report (Date of earliest event reported) Sepracor Inc.(Exact Name of Registrant as Specified in Charter) Delaware – - (State or Other Juris- (Commission (IRS… Sepracor Inc. Reports Fourth Quarter and Full-Year Results, Forecasts Stronger Revenue Growth for Sepracor Inc. (Nasdaq SEPR) today announced its consolidated financial results for the fourth quarter and full-year ended . As announced in Sepracor s Current Report on Form -K, which was filed with the Securities and Exchange Commission on Sepracor has concluded that certain of its previously filed financial statements should no longer be relied upon due to matters relating to the company s government pricing. As a result, the company s management,… . wire (USA) – Wal-Mart Launches Phase Two of Prescription Program With New Medications and Increased Savings, Company removes more than million from healthcare system in first year of program PRNewswire-FirstCall — Wal-Mart Stores, Inc. (NYSE WMT) today announced phase two of its prescription program with changes that will help even more Americans deal with the high-cost of healthcare. The program — which has already saved Americans more than million in its first year — has been expanded in two key ways * More medicines covering more categories — Important prescription medicines have been added to the program covering glaucoma, attention deficit… . wire (Spanish version) – Wal-Mart lanza la segunda fase del programa de recetas con nuevos medicamentos de y ores ahorros, La compa��a elimina m�s de millones del sistema de atenci�n m�dica en el primer a�o del programa de PRNewswire-FirstCall — Wal-Mart Stores, Inc. (NYSE WMT) anunci� hoy la segunda fase de su programa de recetas por , con cambios que ayudan a�n m�s a los norteamericanos a afrontar el alto costo del cuidado de la salud. El programa –que ya le ha ahorrado a los norteamericanos m�s de millones en su primer a�o– se ha ampliado en dos formas fundamentales * M�s medicinas cubriendo m�s categor�as — Se han a�adido importantes medicinas por receta al programa de cubriendo el… . wire (Spanish version) – Wal-Mart lanza la segunda fase del programa de recetas con nuevos medicamentos de y ores ahorros, La compa��a elimina m�s de millones del sistema de atenci�n m�dica en el primer a�o del programa de PRNewswire-FirstCall — Wal-Mart Stores, Inc. (NYSE WMT) anunci� hoy la segunda fase de su programa de recetas por , con cambios que ayudan a�n m�s a los norteamericanos a afrontar el alto costo del cuidado de la salud. El programa –que ya le ha ahorrado a los norteamericanos m�s de millones en su primer a�o– se ha ampliado en dos formas fundamentales * M�s medicinas cubriendo m�s categor�as — Se han a�adido importantes medicinas por receta al programa de cubriendo el… . FD (FAIR DISCLOSURE) WIRE – Q Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Greetings, ladies and gentlemen, and welcome to the Teva Pharmaceutical Industries Ltd. first quarter results conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Kevin Mannix of Teva Pharmaceutical Industries Ltd. Thank you, Mr. Mannix, you … . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Mannix, Teva Pharmaceutical, IR . Shlomo Yanai, Teva Pharmaceutical, President, CEO . George Barnett, Teva Pharmaceutical, EVP Global Pharmaceutical Markets, President COO Teva North America . Dan Suesskind, Teva Pharmaceutical, CFO . Tim Chiang, FTN Midwest, Analyst . Robert Bonte-Friedheim, Citigroup, Analyst . Randall Stanicky, Goldman Sachs, Analyst . Bill Marth, Teva Pharmaceutical, President CEO Teva Pharmaceuticals USA . Rich Silver, Lehman… . FD (FAIR DISCLOSURE) WIRE – Q Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Greetings, ladies and gentlemen, and welcome to the Teva Pharmaceutical Industries Ltd. first quarter results conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Kevin Mannix of Teva Pharmaceutical Industries Ltd. Thank you, Mr. Mannix, you … . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Mannix, Teva Pharmaceutical, IR . Shlomo Yanai, Teva Pharmaceutical, President, CEO . George Barnett, Teva Pharmaceutical, EVP Global Pharmaceutical Markets, President COO Teva North America . Dan Suesskind, Teva Pharmaceutical, CFO . Tim Chiang, FTN Midwest, Analyst . Robert Bonte-Friedheim, Citigroup, Analyst . Randall Stanicky, Goldman Sachs, Analyst . Bill Marth, Teva Pharmaceutical, President CEO Teva Pharmaceuticals USA . Rich Silver, Lehman… . EDGAR Online -K, -Q Glimpse Feed (USA) – -Q SCHERING PLOUGH CORP Item . Management’s Discussion and Analysis of Financial Condition and Results of Operations EXECUTIVE OVERVIEW Overview of Schering-Plough Schering-Plough discovers, develops, manufactures and markets medical therapies and treatments to enhance human health. Schering-Plough also markets leading consumer brands in the over-the-counter (OTC), foot care and sun care markets and operates a global animal health business. There are two sources of new products … –